177 related articles for article (PubMed ID: 11083639)
1. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.
Fung-Tomc JC; Minassian B; Kolek B; Huczko E; Aleksunes L; Stickle T; Washo T; Gradelski E; Valera L; Bonner DP
Antimicrob Agents Chemother; 2000 Dec; 44(12):3351-6. PubMed ID: 11083639
[TBL] [Abstract][Full Text] [Related]
2. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.
Fung-Tomc J; Minassian B; Kolek B; Washo T; Huczko E; Bonner D
J Antimicrob Chemother; 2000 Apr; 45(4):437-46. PubMed ID: 10747819
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients.
Rolston KV; Frisbee-Hume S; LeBlanc BM; Streeter H; Ho DH
Diagn Microbiol Infect Dis; 2002 Oct; 44(2):187-94. PubMed ID: 12458127
[TBL] [Abstract][Full Text] [Related]
4. The in vitro activity of BMS-284756, a new des-fluorinated quinolone.
Weller TM; Andrews JM; Jevons G; Wise R
J Antimicrob Chemother; 2002 Jan; 49(1):177-84. PubMed ID: 11751785
[TBL] [Abstract][Full Text] [Related]
5. Synergistic activity of the novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species.
Fung-Tomc JC; Gradelski E; Valera L; Huczko E; Bonner DP
Int J Antimicrob Agents; 2002 Jul; 20(1):57-60. PubMed ID: 12127712
[TBL] [Abstract][Full Text] [Related]
6. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
Barry AL; Fuchs PC
J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of BAY 12-8039, a new fluoroquinolone.
Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
[TBL] [Abstract][Full Text] [Related]
8. Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams.
Gradelski E; Valera L; Kolek B; Bonner D; Fung-Tomc J
Int J Antimicrob Agents; 2001 Jul; 18(1):43-8. PubMed ID: 11463525
[TBL] [Abstract][Full Text] [Related]
9. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.
Nilius AM; Shen LL; Hensey-Rudloff D; Almer LS; Beyer JM; Balli DJ; Cai Y; Flamm RK
Antimicrob Agents Chemother; 2003 Oct; 47(10):3260-9. PubMed ID: 14506039
[TBL] [Abstract][Full Text] [Related]
10. In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.
Tanaka M; Yamazaki E; Chiba M; Yoshihara K; Akasaka T; Takemura M; Sato K
Antimicrob Agents Chemother; 2002 Mar; 46(3):904-8. PubMed ID: 11850285
[TBL] [Abstract][Full Text] [Related]
11. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study.
Soussy CJ; Nguyen J; Goldstein F; Dabernat H; Andremont A; Leclercq R; Drugeon H; Cavallo P; Chardon H; Etienne J; Rio Y; Courvalin P
Clin Microbiol Infect; 2003 Oct; 9(10):997-1005. PubMed ID: 14616741
[TBL] [Abstract][Full Text] [Related]
12. Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.
Rhomberg PR; Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2001; 40(1-2):45-9. PubMed ID: 11448563
[TBL] [Abstract][Full Text] [Related]
13. In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients.
Rolston KV; Vaziri I; Frisbee-Hume S; Streeter H; LeBlanc B
Chemotherapy; 2004 Nov; 50(5):214-20. PubMed ID: 15523180
[TBL] [Abstract][Full Text] [Related]
14. The in-vitro activity of PD127,391, a new quinolone.
King A; Boothman C; Phillips I
J Antimicrob Chemother; 1988 Aug; 22(2):135-41. PubMed ID: 3182416
[TBL] [Abstract][Full Text] [Related]
15. Comparative antianaerobic activity of BMS 284756.
Hoellman DB; Kelly LM; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2001 Feb; 45(2):589-92. PubMed ID: 11158759
[TBL] [Abstract][Full Text] [Related]
16. Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations.
Lawrence LE; Frosco M; Ryan B; Chaniewski S; Yang H; Hooper DC; Barrett JF
Antimicrob Agents Chemother; 2002 Jan; 46(1):191-5. PubMed ID: 11751133
[TBL] [Abstract][Full Text] [Related]
17. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.
Visalli MA; Bajaksouzian S; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1997 Jul; 41(7):1475-81. PubMed ID: 9210669
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
Ryan BM; Mazzucco CE; Lawrence LE; Ho H; Warr G; Barrett JF; Frosco M
Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):27-34. PubMed ID: 11913498
[TBL] [Abstract][Full Text] [Related]
19. In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients.
Rolston KV; Frisbee-Hume S; LeBlanc B; Streeter H; Ho DH
Diagn Microbiol Infect Dis; 2003 Oct; 47(2):441-9. PubMed ID: 14522520
[TBL] [Abstract][Full Text] [Related]
20. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
Cunha BA; Qadri SM; Ueno Y; Walters EA; Domenico P
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]